Profiling protein expression and interactions: Proximity ligation as a tool for personalized medicine

Journal of Internal Medicine

Volumn 268, Issue 3, 2010, Pages 232-245

  Blokzijl, A ^a   Friedman, M ^a   Ponten F ^a   Landegren, U ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

biomarkers; in vitro diagnostics; personalized medicine; post translational modifications; protein protein interactions; proximity ligation assay

Indexed keywords

BIOLOGICAL MARKER; CETUXIMAB; CYTOTOXIC AGENT; EPHRIN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEMOGLOBIN; IMATINIB; K RAS PROTEIN; NOTCH1 RECEPTOR; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN P53; STROMAL CELL DERIVED FACTOR 1; TAMOXIFEN;

ASPIRATION CYTOLOGY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STEM CELL; CARCINOGENESIS; CELL EXPANSION; CELL SURVIVAL; DIFFERENTIAL DIAGNOSIS; DNA SEQUENCE; DNA STRAND; ELECTROPHORETIC MOBILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METASTASIS; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; MULTIPLEX POLYMERASE CHAIN REACTION; NEEDLE BIOPSY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PROTEOMICS; PROXIMITY LIGATION ASSAY; RADIOIMMUNOASSAY; RETROSPECTIVE STUDY; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO; SIGNAL TRANSDUCTION; SUMOYLATION; TISSUE MICROARRAY; UBIQUITINATION; WESTERN BLOTTING;

BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; GENE EXPRESSION PROFILING; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; TUMOR MARKERS, BIOLOGICAL;

EID: 77955234502     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2010.02256.x     Document Type: Review

References (68)

1. Rimm DL. What brown cannot do for you. Nat Biotechnol 2006 24 : 914 916.
2. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002 1 : 845 867.
3. Uhlen M, Bjorling E, Agaton C et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 2005 4 : 1920 1932.
4. Hortin GL, Carr SA, Anderson NL. Introduction: advances in protein analysis for the clinical laboratory. Clin Chem 2010 56 : 149 151.
5. Orimo A, Gupta PB, Sgroi DC et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005 121 : 335 348.
6. Suwa H, Ohshio G, Okada N et al. Clinical significance of serum p53 antigen in patients with pancreatic carcinomas. Gut 1997 40 : 647 653.
7. Wang P, Whiteaker JR, Paulovich AG. The evolving role of mass spectrometry in cancer biomarker discovery. Cancer Biol Ther 2009 8 : 1083 1094.
8. Wu CC, Hsu CW, Chen CD et al. Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas. Mol Cell Proteomics 2010 9 : 1100 1117.
9. Clamp M, Fry B, Kamal M et al. Distinguishing protein-coding and noncoding genes in the human genome. Proc Natl Acad Sci USA 2007 104 : 19428 19433.
10. Ponten F, Jirstrom K, Uhlen M. The Human Protein Atlas - a tool for pathology. J Pathol 2008 216 : 387 393.
11. Ponten F, Gry M, Fagerberg L et al. A global view of protein expression in human cells, tissues, and organs. Mol Syst Biol 2009 5 : 337.
12. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987 317 : 909 916.
13. Laurent-Puig P, Cayre A, Manceau G et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009 27 : 5924 5930.
14. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med 2009 15 : 1010 1012.
15. Koch U, Krause M, Baumann M. Cancer stem cells at the crossroads of current cancer therapy failures-radiation oncology perspective. Semin Cancer Biol 2010 20 : 116 124.
16. Meng RD, Shelton CC, Li YM et al. gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res 2009 69 : 573 582.
17. Sikandar SS, Pate KT, Anderson S et al. NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res 2010 70 : 1469 1478.
18. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007 316 : 1039 1043.
19. Pennell NA, Lynch TJ Jr. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 2009 14 : 399 411.
20. Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 2010 56 : 177 185.
21. Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest 1960 39 : 1157 1175.
22. Daniel YA, Turner C, Haynes RM, Hunt BJ, Dalton RN. Quantification of hemoglobin A2 by tandem mass spectrometry. Clin Chem 2007 53 : 1448 1454.
23. Lequin RM. Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA). Clin Chem 2005 51 : 2415 2418.
24. Burnette WN. "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate - polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem 1981 112 : 195 203.
25. Sano T, Smith CL, Cantor CR. Immuno-PCR: very sensitive antigen detection by means of specific antibody-DNA conjugates. Science 1992 258 : 120 122.
26. Kallioniemi OP, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001 10 : 657 662.
27. Decaestecker C, Lopez XM, D'Haene N et al. Requirements for the valid quantification of immunostains on tissue microarray materials using image analysis. Proteomics 2009 9 : 4478 4494.
28. Stromberg S, Bjorklund MG, Asplund C et al. A high-throughput strategy for protein profiling in cell microarrays using automated image analysis. Proteomics 2007 7 : 2142 2150.
29. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002 8 : 1323 1327.
30. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 2008 21 (Suppl. 2 S8 15.
31. Goodwin RJ, Pennington SR, Pitt AR. Protein and peptides in pictures: imaging with MALDI mass spectrometry. Proteomics 2008 8 : 3785 3800.
32. Caprioli RM, Farmer TB, Gile J. Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. Anal Chem 1997 69 : 4751 4760.
33. Seeley EH, Caprioli RM. Molecular imaging of proteins in tissues by mass spectrometry. Proc Natl Acad Sci USA 2008 105 : 18126 18131.
34. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006 5 : 573 588.
35. Picotti P, Bodenmiller B, Mueller LN, Domon B, Aebersold R. Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell 2009 138 : 795 806.
36. Schroder C, Jacob A, Tonack S et al. Dual-color proteomic profiling of complex samples with a microarray of 810 cancer-related antibodies. Mol Cell Proteomics 2010 9 : 1271 1280.
37. Mandell JW. Immunohistochemical assessment of protein phosphorylation state: the dream and the reality. Histochem Cell Biol 2008 130 : 465 471.
38. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998 339 : 1609 1618.
39. Murphy LC, Skliris GP, Rowan BG et al. The relevance of phosphorylated forms of estrogen receptor in human breast cancer in vivo. J Steroid Biochem Mol Biol 2009 114 : 90 5.
40. Miao H, Li DQ, Mukherjee A et al. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 2009 16 : 9 20.
41. Venkatesan K, Rual JF, Vazquez A et al. An empirical framework for binary interactome mapping. Nat Methods 2009 6 : 83 90.
42. Rhodes DR, Tomlins SA, Varambally S et al. Probabilistic model of the human protein-protein interaction network. Nat Biotechnol 2005 23 : 951 959.
43. Ruepp A, Waegele B, Lechner M et al. CORUM: the comprehensive resource of mammalian protein complexes - 2009. Nucleic Acids Res 2010 38 : D497 501.
44. Keshava Prasad TS, Goel R, Kandasamy K et al. Human protein reference database - 2009 update. Nucleic Acids Res 2009 37 : D767 72.
45. Cusick ME, Yu H, Smolyar A et al. Literature-curated protein interaction datasets. Nat Methods 2009 6 : 39 46.
46. Lewis AC, Saeed R, Deane CM. Predicting protein-protein interactions in the context of protein evolution. Mol Biosyst 2010 6 : 55 64.
47. Desmedt C, Sperinde J, Piette F et al. Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH. Diagn Mol Pathol 2009 18 : 22 9.
48. Shi Y, Huang W, Tan Y et al. A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue. Diagn Mol Pathol 2009 18 : 11 21.
49. Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C, Parry G. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. Breast Cancer Res Treat 2009
50. Loupakis F, Ruzzo A, Cremolini C et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009 101 : 715 721.
51. Fredriksson S, Gullberg M, Jarvius J et al. Protein detection using proximity-dependent DNA ligation assays. Nat Biotechnol 2002 20 : 473 477.
52. Söderberg O, Gullberg M, Jarvius M et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 2006 3 : 995 1000.
53. Gullberg M, Gustafsdottir SM, Schallmeiner E et al. Cytokine detection by antibody-based proximity ligation. Proc Natl Acad Sci USA 2004 101 : 8420 8424.
54. Bjarnegard M, Enge M, Norlin J et al. Endothelium-specific ablation of PDGFB leads to pericyte loss and glomerular, cardiac and placental abnormalities. Development 2004 131 : 1847 1857.
55. Gustafsdottir SM, Nordengrahn A, Fredriksson S et al. Detection of individual microbial pathogens by proximity ligation. Clin Chem 2006 52 : 1152 1160.
56. Schallmeiner E, Oksanen E, Ericsson O et al. Sensitive protein detection via triple-binder proximity ligation assays. Nat Methods 2007 4 : 135 137.
57. Darmanis S, Nong RY, Hammond M et al. Sensitive plasma protein analysis by microparticle-based proximity ligation assays. Mol Cell Proteomics 2010 9 : 327 335.
58. Ronquist KG, Ronquist G, Larsson A, Carlsson L. Proteomic analysis of prostate cancer metastasis-derived prostasomes. Anticancer Res 2010 30 : 285 290.
59. Fredriksson S, Horecka J, Brustugun OT et al. Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer. Clin Chem 2008 54 : 582 589.
60. Ericsson O, Jarvius J, Schallmeiner E et al. A dual-tag microarray platform for high-performance nucleic acid and protein analyses. Nucleic Acids Res 2008 36 : e45.
61. Allalou A, Wahlby C. BlobFinder, a tool for fluorescence microscopy image cytometry. Comput Methods Programs Biomed 2009 94 : 58 65.
62. Leuchowius KJ, Weibrecht I, Landegren U, Gedda L, Soderberg O. Flow cytometric in situ proximity ligation analyses of protein interactions and post-translational modification of the epidermal growth factor receptor family. Cytometry A 2009 75 : 833 839.
63. Zieba A, Wahlby C, Hjelm F et al. Bright-field microscopy visualization of proteins and protein complexes by in situ proximity ligation with peroxidase detection. Clin Chem 2010 56 : 99 110.
64. Jarvius M, Paulsson J, Weibrecht I et al. In situ detection of phosphorylated platelet-derived growth factor receptor beta using a generalized proximity ligation method. Mol Cell Proteomics 2007 6 : 1500 1509.
65. Haj FG, Verveer PJ, Squire A, Neel BG, Bastiaens PI. Imaging sites of receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum. Science 2002 295 : 1708 1711.
66. Jones SM, Kazlauskas A. Growth-factor-dependent mitogenesis requires two distinct phases of signalling. Nat Cell Biol 2001 3 : 165 172.
67. Leuchowius KJ, Jarvius M, Wickstrom M et al. High content screening for inhibitors of protein interactions and post-translational modifications in primary cells by proximity ligation. Mol Cell Proteomics 2010 9 : 178 183.
68. Conze T, Carvalho AS, Landegren U et al. MUC2 mucin is a major carrier of the cancer-associated sialyl-Tn antigen in intestinal metaplasia and gastric carcinomas. Glycobiology 2010 20 : 199 206.